Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.2 EUR | -17.32% | -.--% | -.--% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Low profitability weakens the company.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 1.93Cr | - | ||
+40.80% | 5.37TCr | B- | ||
+34.35% | 3.89TCr | A | ||
-8.05% | 3.88TCr | B | ||
-8.98% | 2.73TCr | C | ||
+10.69% | 2.59TCr | B- | ||
-16.21% | 2.03TCr | B | ||
+31.00% | 1.28TCr | B+ | ||
+28.51% | 1.22TCr | C+ | ||
-1.67% | 1.2TCr | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MEIP Stock
- MMI0 Stock
- Ratings MEI Pharma, Inc.